Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.
"Halozyme is pleased to have received favorable reviews that recognize the merit of each of the four applications that we submitted to this program," stated Jonathan Lim, M.D., president and CEO. "This cash award will be utilized to help further advance our product development projects that have the potential to deliver breakthrough medical discoveries for patients with debilitating medical conditions and diseases."
Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions